AzurRx BioPharma, Inc.
AZRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5,702 | $16,439 | $16,439 | $11,851 |
| - Cash | $2,517 | $4 | $59 | $163 |
| + Debt | $836 | $836 | $836 | $141 |
| Enterprise Value | $4,020 | $17,270 | $17,216 | $11,828 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$935 | -$639 | -$821 | -$4,443 |
| % Margin | – | – | – | – |
| Net Income | -$1,153 | -$998 | -$1,260 | $31,577 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.75 |
| % Growth | -257.1% | 25% | 89.8% | – |
| Operating Cash Flow | -$856 | -$55 | -$819 | $7,368 |
| Capital Expenditures | $0 | $0 | $0 | $74 |
| Free Cash Flow | -$856 | -$55 | -$819 | $7,442 |